FOXO4-DRI

Senolytic Peptide

FOXO4-DRI

FOXO4-DRI is a synthetic peptide widely studied for its role in FOXO4-p53 interaction disruption, cellular senescence signaling, and senescent cell clearance pathways.

1
$199.99
Most Popular
Best Value
Est. delivery Jul 20 - Jul 22
Free shipment protection
Secure checkout
We accept: Visa Mastercard American Express
Free shipping on orders over $200
Damage protection on every order
Secure checkout 256-bit SSL
Certificate of Analysis
Tested for Identification, Purity, Mass, Endotoxins, Sterility, and Heavy Metals
LATEST
PURITY
Variant FOXO4-DRI 10MG
Lot #
Labeled 10MG
Actual
Tested
Heavy Metals
Endotoxins
Sterility
Analysis Pending
Compound Information
Pharmaceutical Specifications
Molecular Profile
What Is FOXO4-DRI?
TypeSynthetic peptide
CAS Number1802756-54-2
Molecular FormulaC₁₁₂H₁₉₀N₃₄O₃₃
Molecular Weight2,537.95 g/mol
Amino Acids18
Storage Requirements
Stability Information
Lyophilized (powder)
-20°C  ·  24+ months
Reconstituted
2-8°C  ·  ~30 days
Research
Sources & References
CELL (CELL PRESS)
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
2017  ·  DOI: 10.1016/j.cell.2017.02.031
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WFJ, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ
View Source
NATURE COMMUNICATIONS (SPRINGER NATURE)
The Disordered p53 Transactivation Domain Is the Target of FOXO4 and the Senolytic Compound FOXO4-DRI
2025  ·  DOI: 10.1038/s41467-025-60881-4
Bourgeois B, Stryeck S, Baar MP, Madl T, de Keizer PLJ
View Source
AGING (IMPACT JOURNALS)
FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency by Targeting Senescent Leydig Cells in Aged Mice
2020  ·  DOI: 10.18632/aging.102682
Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M, Xia K, Feng X, Li Y, Liang X, Sun X, Deng C, Liu G
View Source
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (FRONTIERS)
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells from In Vitro Expanded Human Chondrocytes
2021  ·  DOI: 10.3389/fbioe.2021.677576
Huang Y, He Y, Makarcyzk MJ, Lin H
View Source
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (WILEY)
FOXO4 Peptide Targets Myofibroblast and Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice Through ECM-Receptor Interaction Pathway
2022  ·  DOI: 10.1111/jcmm.17247
Han X, et al.
View Source
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (FRONTIERS)
FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Signaling Pathway
2025  ·  DOI: 10.3389/fbioe.2025.1729166
Wang Y, et al.
View Source
CELL (CELL PRESS)
Cellular Senescence: Defining a Path Forward
2019  ·  DOI: 10.1016/j.cell.2019.10.005
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, Gil J, Hara E, Krizhanovsky V, Jurk D, Maier AB, Narita M, Niedernhofer L, Passos JF, Robbins PD, Schmitt CA, Sedivy J, Vougas K, von Zglinicki T, Zhou D, Serrano M, Demaria M
View Source
NATURE REVIEWS DRUG DISCOVERY (SPRINGER NATURE)
Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-in-Human, Open-Label, Pilot Study
2019  ·  DOI: 10.1016/j.ebiom.2019.08.069
Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL
View Source
NPJ AGING (SPRINGER NATURE)
Emerging Strategies in Senotherapeutics: From Broad-Spectrum Senolysis to Precision Reprogramming
2026  ·  DOI: 10.1038/s41514-026-00355-z
Krishnakumar IM, et al.
View Source
CELL (CELL PRESS)
Hallmarks of Aging: An Expanding Universe
2023  ·  DOI: 10.1016/j.cell.2022.11.001
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G
View Source
FOXO4-DRI $199.99

Senolytic Peptide

FOXO4-DRI is a synthetic peptide widely studied for its role in FOXO4-p53 interaction disruption, cellular senescence signaling, and senescent cell clearance pathways.

Additional information

Size:

10MG